2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.02F.07 Targeting NRAS Increases Lung Adenocarcinoma Sensitivity to Paclitaxel Chemotherapy

Pdf Summary

The study investigates the role of NRAS in lung adenocarcinoma (LUAD), particularly in relation to resistance to the chemotherapy drug paclitaxel. Lung adenocarcinoma is a major type of non-small cell lung cancer (NSCLC), which is noted for high mortality rates due to drug resistance. The research focuses on targeting NRAS as a potential method to overcome this resistance, ultimately aiming to improve treatment outcomes for patients.<br /><br />Key findings from the study indicate that increased NRAS expression in LUAD patients correlates with poorer clinical outcomes and heightened drug resistance. The researchers propose that targeting NRAS could effectively reduce this resistance, making paclitaxel more effective. To support this, a multi-step study was conducted, comparing NRAS expression between LUAD and normal tissues and correlating its expression with clinical outcomes using The Cancer Genome Atlas (TCGA) data. The study involved NRAS knockdown in LUAD cell lines, which showed increased sensitivity to paclitaxel.<br /><br />The researchers also explored the relationship between NRAS and other genes involved in paclitaxel resistance, discovering a strong correlation between NRAS expression and resistance pathways, particularly involving the RAS signaling pathway. Furthermore, the study incorporated enrichment analysis using KEGG pathways to validate their findings and to examine NRAS's relationship with immune infiltration.<br /><br />The study concludes that targeting NRAS could be a promising strategy to counteract paclitaxel resistance, thus enhancing the efficacy of existing chemotherapy regimens. It encourages further research into the development of NRAS-targeted therapies that could be combined with standard chemotherapy to improve clinical outcomes for LUAD patients.<br /><br />The research was supported by various grants from Chinese scientific foundations and represents a potential advancement in the treatment of lung adenocarcinoma.

Asset Subtitle

Yifei Liu

Meta Tag

Speaker Yifei Liu

Topic Tumor Biology – Preclinical Biology

Keywords

NRAS

lung adenocarcinoma

paclitaxel resistance

non-small cell lung cancer

drug resistance

The Cancer Genome Atlas

RAS signaling pathway

KEGG pathways

immune infiltration

NRAS-targeted therapies